A recent study conducted at a leading pediatric center in North India has shed light on the efficacy and cost-effectiveness of hormonal therapies in treating infantile epileptic spasms syndrome (IESS) among children. The research provides compelling evidence favoring the use of synthetic adrenocorticotrophic hormone (ACTH) over oral prednisolone, offering valuable insights for both caregivers and healthcare providers.
Study Overview and Methodology
The prospective observational study encompassed 93 children aged between 3 to 18 months diagnosed with IESS. Participants were administered either ACTH or oral prednisolone, with the primary outcomes measuring the cessation of epileptic spasms (ES), incidence of treatment-emergent adverse events (TEAEs), and improvements in Health-Related Quality of Life (HRQoL). Additionally, a cost-effectiveness analysis (CEA) was performed using a decision-tree model to assess the financial implications of each treatment option.
Key Findings and Implications
Results indicated that 53% of children treated with ACTH experienced cessation of ES within two weeks, compared to 34% in the prednisolone group. Although the difference in adverse events between the two groups was not statistically significant, children receiving ACTH demonstrated a notable improvement in HRQoL scores. The CEA revealed that while ACTH has a higher incremental cost-effectiveness ratio (ICER) at approximately $1,468.90 USD, it offers substantial benefits in terms of treatment efficacy and quality of life improvements.
Inference Highlights:
- ACTH significantly increases the likelihood of ES cessation compared to prednisolone.
- Short-term quality of life scores improve markedly with ACTH treatment.
- Despite higher costs, ACTH presents a favorable cost-effectiveness profile for IESS management.
The study underscores the superior performance of ACTH in managing IESS, balancing both clinical outcomes and economic considerations. For families grappling with the burdens of infantile epileptic spasms, ACTH emerges as a more effective treatment option that, despite its higher initial costs, offers better long-term benefits in controlling seizures and enhancing the quality of life for young patients.
Healthcare providers are encouraged to consider ACTH as a first-line treatment for IESS, especially in settings where the long-term benefits justify the upfront expenses. Policymakers and insurance companies might also take note of these findings to support coverage decisions that align with both clinical efficacy and economic sustainability.
Families and clinicians now have robust data to guide treatment choices, ensuring that decisions are informed by both health outcomes and financial impacts. As further research emerges, the medical community can build on these insights to optimize therapeutic strategies for IESS, ultimately improving the lives of affected children and their families.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
